Nine tumors were tested with Nanocind CINSARC® signature and all were classified in low risk of recurrence. We propose, based on our observations, a diagnostic approach of these challenging lesions.
8 months ago
Journal
|
TP53 (Tumor protein P53) • FH (Fumarate Hydratase)